Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Sponsor
National Cancer Institute (NCI)
Study ID
NCT02243605
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Metastatic Ewing Sarcoma
  • Metastatic Osteosarcoma
  • Recurrent Ewing Sarcoma
  • Recurrent Osteosarcoma
  • Stage III Osteosarcoma AJCC v7
  • Stage IV Osteosarcoma AJCC v7
  • Stage IVA Osteosarcoma AJCC v7
  • Stage IVB Osteosarcoma AJCC v7
  • Unresectable Ewing Sarcoma
  • Unresectable Osteosarcoma

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial studies how well cabozantinib s-malate works in treating patients with osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of improvement. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may also prevent the growth of new blood vessels that tumors need to grow.

Key Dates

Start date
Dec 19, 2014
Status verified
Jun 2026
Primary completion
Jun 30, 2019
Completion
Jul 11, 2026

Study Design

Enrollment
90 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (cabozantinib s-malate)
    Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Non-progression at 6 Months - Osteosarcoma [ Time Frame: At 6 months ]

Related Studies